632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301doi:10.1016/S1359-6349(06)70637-1B. Burtness and J. Manola and A. Argiris and D. Altieri and R....
Dasatinib (SPRYCEL®, BMS-354825) Phase-I/II Study of Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib: Results of the CA... H Sakamaki,S Fujisawa,K Tobinai,... 被引量: 0发表: 2006年 Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia...
uiii 关注 100 粉丝 2700 获赞 8.0万 抖音号:Mmmmmmxsm629IP属地:浙江29岁 最新作品发布时间:2025-01-27 22:40 🦦🦦🦦 私信关注 关注私信 作品50 喜欢 搜索Ta 的作品 视频 日期筛选 131 #tara #daybyday 时代的眼泪跟一下 #tara #daybyday 时代的眼泪跟一下 135 “爱是一种天赋” “爱是...
Here we describe the design of a phase 1b/2, nonrandomized, open-label study of BMS-813160 (small-molecule CCR2/5 dual antagonist) as monotherapy or in combination with chemotherapy or nivolumab in pts with advanced pancreatic or colorectal cancer (NCT03184870).Methods: Approximately 260 pts ...